Genelux Corp. is a high-risk pharmaceutical company based in the United States of America. Specializing in ESG-focused clinical-stage biopharmaceuticals, Genelux Corp. is dedicated to creating innovative oncolytic viral immunotherapies for patients with challenging solid tumor types. Their pipeline includes products like Olvi-Vec (olvimulogene nanivacirepvec) and more.